DV
Dividend Vision

CNXU — Conexeu Sciences Inc. Common Stock

Conexeu Sciences Inc. Common Stock (CNXU)

Total return is -31.9% over the past 0.2 years, 36.7 points behind SPY at 4.8%.

Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for medical aesthetics and tissue repair applications, including investigational collagen gel and extracellular matrix platforms designed as alternatives to conventional fillers and implants. The company does not currently distribute dividends to shareholders. This early-stage biotech company, founded in 2022 and based in Reno, Nevada, appeals to investors seeking equity exposure to the regenerative medicine and medical aesthetics sectors rather than current income.

CNXU key facts

Asset type
Stock
Asset class
Equity
Inception date
05/21/2026
Last close
$8.90
Market cap
$263,034,384
Average volume
244400.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.34